Reviewer’s report

Title: Prevalence of Germline Mutations in the TP53 Gene in Patients with Early-onset Breast Cancer in the Mexican Population

Version: 0 Date: 12 Jan 2018

Reviewer: Amanda Toland

Reviewer's report:

This new revised submission by Gallardo-Alvardo et al. describes a study of 78 early onset breast cancer cases in the Mexican population for whom TP53 germline mutation testing was completed. The authors found a high frequency of TP53 mutations (6.4% in all cases; 9.4% in women 36 years of age and earlier). The authors have addressed all of my previous comments and concerns. There are a few minor points for correction.

Minor:

Introduction line 90: the authors list other genes related to BC risk. Some of them (NBS1, BRIP1) are a bit more controversial to include on the list as some groups do not feel these are associated with increases in risk. Thus, this list could be shorter.

Methods lines 131-133. How were the 78 patients (of the 279 BRCA mutation negative) patients selected for this study. Why weren't all 279 tested?

Gene names should be italized. There are a few cases (such as results line 199) in which this was missed.

Table 3: Should be estrogen receptor not estrogens receptor.

Table 4: Should be 1st, 2nd, 3rd degree relatives

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal